JPRN-C000000376已完成3 期
Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations - Gefitinib vs CBDCA/TXL in untreated NSCLC with EGFR mutations
EJ Gefitinib Study Group0 个研究点目标入组 320 人开始时间: 2008年12月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.With lung fibrosis detectable in chest CT 2.With gefitinib resistant EGFR mutation (T790M) 3.With symptomatic brain metastasis 4.Previous radiotherapy to primary lung cancer 5.With severe co-morbidities 6.With active double cancer
研究者
相似试验
已完成
不适用
Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)on-small cell lung cancerJPRN-UMIN000006340orth-East Japan Study Group345
已完成
3 期
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)advanced non-squamous non-small cell lung cancer harboring EGFR mutaitonJPRN-UMIN000020242Japan Clinical Oncology Group (JCOG)500
尚未招募
3 期
A study to compare Gefitinib tablet with Gefitinib and Chemotherapy inEGFR Mutation Positive Lung cancer patientsCTRI/2022/08/044570Tata Memorial Centre
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
招募中
1 期
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70